P-31: Real World Experience and 12 Month Outcomes for Patients Treated with Teduglutide at an Australian Centre

Introduction: Teduglutide, a recombinant analogue of human glucagon-like peptide-2 (GLP-2), has demonstrated efficacy in clinical trial settings for reducing parenteral support (PS) requirements in patients with short bowel syndrome-intestinal failure (SBS-IF). We describe the real world experience of adult patients treated with 12 months of teduglutide at an Australian, single quaternary centre. Methods: Consecutive SBS-IF patients who received...